Corvidane

Paresh Soni, CEO

20+ years of executive pharmaceutical experience in Cardiovascular diseases and NASH that includes Amarin, Alexion, Pfizer and Albireo. Led the NDA submission and approval of Vascepa®, designed and launched the landmark REDUCE-IT study.

Peggy Berry, VP of Regulatory

28 years of Regulatory experience that includes 5 years with Amarin. Developed and operationalized Regulatory strategy for

Vascepa®. Established and lead Global Regulatory, Quality and Pharmacovigilance functions. Managed clinical trial submissions in the U.S., the EU and Canada. Led meetings with Regulatory authorities globally, including an Advisory Committee at the FDA.

Damion J. Boyer, Co-Founder/COO

6 years experience as CEO of Corvidane. Responsible for initiating Corvidane’s NASH program and forging strategic alliances in the U.S. and Europe, which includes UMC Utrecht and resulted in a non-dilutive subsidy from the Dutch government.

Patrice Binay, VP of Chemistry & CMC

32 years of pharmaceutical Fine Chemistry experience. Synthesis and analytical characterization of Active Pharmaceutical Ingredients, Quality auditing, Industrial Transfer. Development of a new class of anti-inflammatory (H4 Receptor).

Menno van Burken, VP of Commercial

32 years of global pharmaceutical experience across diverse commercial roles with Pfizer. Lead Cardiovascular and Metabolic therapeutic disease initiatives across R&D, Clinical Development, Medical Affairs, Regulatory and Commercial functions (inlcluding pricing market access, competitive intelligence)